Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress
ST. LOUIS, Sept. 03, 2024 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its technology will be prominently featured during the upcoming HRX digital health conference taking place September 5-7, 2024, in Atlanta, Georgia.
HRX, an initiative pioneered by the Heart Rhythm Society (HRS), is focused on exploring digital technologies that advance the boundaries of innovation in cardiovascular medicine.
Stereotaxis CEO, David Fischel, will participate in a roundtable discussion titled “The EP Lab of the Future” on September 5th beginning at 4:45 PM EDT. On September 6th at 9:45 AM EDT, Mr. Fischel will join a distinguished panel of experts, including Dr. Ben D’Souza, Dr. Dan Cooper, and Dr. Peter Weiss for a Joint Session of the Society of Cardiac Robotic Navigation and HRS titled “The Role of Robotics in Present and Future Care of Heart Rhythm Patients.” These sessions highlight the increasing awareness and relevance of robotic technology in improving patient outcomes and advancing the field of cardiac rhythm management.
“We appreciate the opportunity to participate in these discussions with the HRX community as we jointly define a future in which patients and providers benefit from the promise of robotics, connectivity, and digital innovations,” said David Fischel.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
